Carbidopa: Clinical Trials

8 trials of Carbidopa, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

5 completed, 2 terminated, 1 unknown. 8 Phase 4.

By phase and status

PhaseTrialsStatus
Phase 48Completed 5, Terminated 2, Unknown 1

Follow Carbidopa: new trials by email Literature Review of Carbidopa trials Research Report on Carbidopa

Trials (filtered) newest first · largest first

All 8 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Clinical Study of Stalevo in the Treatment of Early Parkinson's Disease
Stalevo, Carbidopa and Levodopa Controlled Release Tablets - Parkinson Disease
Phase 4UnknownSecond Affiliated Hospital, Zhejiang University, School of Medicine1802022-01-012023-02-16
Vigor and the LDR in Parkinson Disease
carbidopa/levodopa, as prescribed by treating physician - Parkinson Disease
Phase 4CompletedUniversity of Michigan192020-02-122025-07-18
L-DOPA vs. Placebo for Depression and Psychomotor Slowing in Older Adults
L-DOPA, Placebo Oral Tablet - Major Depressive Disorder, Dysthymia
Phase 4TerminatedNew York State Psychiatric Institute512019-01-092023-05-22
Norepinephrine-targeted Therapy for Action Control in Parkinson Disease
Droxidopa, Carbidopa - Parkinson Disease
Phase 4CompletedVanderbilt University Medical Center152017-04-182020-01-27
Apokyn for Motor IMProvement of Morning AKinesia Trial (AM IMPAKT)
APOKYN, L-dopa, Trimethobenzamide - Parkinson's Disease, Motor Symptoms
Phase 4CompletedMDD US Operations, LLC a subsidiary of Supernus Pharmaceuticals1272012-12-012023-08-14
Remission of ICD by Switching Dopamine Agonist to Levodopa/Carbidopa
Levodopa/Carbidopa(200mg/50mg), Dopaminergic Agonists - Impulse Control Disorder
Phase 4CompletedSandoz1502012-11-012021-03-10
Long-term Study of Duodopa (Levodopa/Carbidopa) in Advanced Parkinson's: Health Outcomes & Net Economic Impact
Levodopa-carbidopa intestinal gel (LCIG), CADD-Legacy® 1400 ambulatory infusion pump, percutaneous endoscopic gastrostomy tube (PEG tube) - Advanced Idiopathic Parkinson's Disease
Phase 4CompletedAbbVie (prior sponsor, Abbott)772006-03-012016-07-18
Study Of Cabaser and Sinemet CR For The Treatment Of Nighttime Symptoms Associated With Parkinson's Disease.
cabergoline, controlled-release levodopa / carbidopa - Parkinson Disease
Phase 4TerminatedPfizer2202004-07-012007-05-25

Conditions studied

Parkinson Disease (5)  ·  Depression (1)  ·  Depressive Disorder, Major (1)  ·  Disruptive, Impulse Control, and Conduct Disorders (1)  ·  Dysthymic Disorder (1)

Sponsors

AbbVie (prior sponsor, Abbott) (1)  ·  MDD US Operations, LLC a subsidiary of Supernus Pharmaceuticals (1)  ·  New York State Psychiatric Institute (1)  ·  Pfizer (1)  ·  Sandoz (1)  ·  Second Affiliated Hospital, Zhejiang University, School of Medicine (1)  ·  University of Michigan (1)  ·  Vanderbilt University Medical Center (1)

Countries

United States (4)  ·  Australia (1)  ·  China (1)  ·  Italy (1)  ·  South Korea (1)  ·  Spain (1)

Top investigators

Bret Rutherford, MD (1)  ·  Gianpiera H. Ceresoli-Borroni, PhD (1)  ·  Jinwhan Cho, MD (1)  ·  Katherine McDonell, MD (1)  ·  Lars Bergmann, MD (1)  ·  Roger Albin (1)

Results publications

PMID 30361296

NIH funding

2005 (1), R21NS114749 (1), R33MH110029 (1)